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Abstract Inhibition of vascular endothelial growth factor
increases response rates to chemotherapy and progression-free
survival in glioblastoma. However, resistance invariably occurs,
prompting the urgent need for identification of synergizing
agents. One possible strategy is to understand tumor adaptation
to microenvironmental changes induced by antiangiogenic
drugs and test agents that exploit this process. We used an in
vivo glioblastoma-derived xenograft model of tumor escape in
presence of continuous treatment with bevacizumab. U87-MG
or U118-MG cells were subcutaneously implanted into either
BALB/c SCID or athymic nude mice. Bevacizumab was given
by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/
or dichloroacetate (DCA)was administered by oral gavage twice
daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm3
and continued until tumors reached approximately 1.5–2.0 cm3.
Microarray analysis of resistant U87 tumors revealed coordinat-
ed changes at the level of metabolic genes, in particular, a
widening gap between glycolysis and mitochondrial respiration.
There was a highly significant difference between U87-MG-
implanted athymic nude mice 1 week after drug treatment. By
2 weeks of treatment, bevacizumab and DCA together dramat-
ically blocked tumor growth compared to either drug alone.
Similar results were seen in athymic nude mice implanted with
U118-MG cells. We demonstrate for the first time that reversal
of the bevacizumab-induced shift in metabolism using DCA is
detrimental to neoplastic growth in vivo. As DCA is viewed as a
promising agent targeting tumor metabolism, our data establish
the timely proof of concept that combining it with antiangio-
genic therapy represents a potent antineoplastic strategy.
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Introduction
Molecular therapies targeting neo-angiogenesis and, in particu-
lar, vascular endothelial growth factor (VEGF) have shown
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antitumor activity in a variety of clinical contexts [1]. Glioblas-
toma (GBM) is a highly vascularized and lethal primary brain
tumor, with median survival of approximately 12–14 months,
and therefore, represents an important target for antiangiogenic
drugs [2]. Bevacizumab, a humanized anti-VEGF antibody, is
currently approved by the Food and Drug Administration as a
second-line treatment of GBM, and ongoing clinical trials aim at
assessing its potential as a first-line agent [3]. However, as
VEGF blockade prolongs progression-free survival but not
overall survival, it is imperative to identify strategies that in-
crease its impact and delay the onset of resistance [4]. For
example, limited progress has been achieved in combination
with irinotecan; however, no impact on overall survival could be
demonstrated [5]. One major limitation in developing synergis-
tic combinations centered on anti-VEGF agents is lack of robust
clinical data as tumors that are becoming resistant to these agents
are not routinely available for further analyses. Moreover, the
cellular and molecular consequences of anti-VEGF treatment
are still insufficiently understood. Detailed information at the
molecular level on how bevacizumab affects GBM during an
extended timeframe is not only essential to our understanding of
tumor adaptive responses and subsequent treatment failure but
also to the development of rational combination therapies.
We, therefore, sought to determine the tumor response to
bevacizumab at the phenotypic and molecular level in xeno-
graft models derived from GBM cell lines. By extending the
models until eventual therapeutic failure despite continuous
bevacizumab treatment, we aimed to capture the tumor adap-
tive programs and the corresponding rewiring of themolecular
pathways using microarray analysis. We hypothesized that the
core mechanisms of resistance would be reflected in alteration
of these pathways, and small molecules which interfere with
these processes represent realistic candidates to increase the
potency of bevacizumab. Bioinformatic analysis revealed that
resistant tumors exhibit a strong hypoxia-inducible factor
(HIF) signature and shift from mitochondrial respiration to
glycolysis. Reactivation of mitochondrial respiration with the
orphan drug dichloroacetate (DCA) enhances the transient
effect of bevacizumab, in contrast to the lack of additive effect
of 2-deoxyglucose (2-DG), which primarily targets glycolysis.
Our data provide insights into the plasticity of tumor metab-
olism in response to therapeutic challenges and suggest novel
opportunities for synergistic interventions.
Materials and methods
In vivo tumorigenicity
All protocols were carried out under Indiana University Insti-
tutional Animal Care and Use Committee, and UK Home
Office approved protocols and regulations. 107 U87-MG cells
(purchased fromATCC) were implanted into 6- to 8-week-old
female BALB/c SCID mice (Harlan Sprague Dawley, Inc.)
subcutaneously, as 100-μL cell suspensions with an equal
volume of Matrigel (BD Bioscience). Tumors were measured
twice a week with a caliper, and volumes were calculated
using the formula length×width×height×0.52. Once the tu-
mor volume reached 150 mm3, mice were randomized into
two groups with starting cohort sizes of five mice per group
and treatment of bevacizumab (Roche) injected intraperito-
neally every 3 days at a dose of 10 mg/kg or saline control
begun. Treatment was continued until tumors grew to approx-
imately a volume of 600–800 mm3 at which point the mice
were euthanized and tumors were surgically excised quickly.
For the athymic nude mice xenograft models, either U87-MG
cells were implanted as above into 4- to 8-week-old female
mice (Harlan Laboratories, Indianapolis, IN, USA), or 7×106
U118-MG cells (purchased from ATCC) were grafted. Tumor
fragments were either processed by formalin fixation before
paraffin embedding for IHC or frozen for later RNA extrac-
tion, as described previously [6].
Drug delivery protocols for combination studies
DCA was administered by oral gavage twice daily at 50
mg/kg/dose in sterile water (vehicle control was sterile
water). This dose was based on published reports and allo-
metric scaling. Thus, 100 mg/kg per mouse per day trans-
lates into approximately 13 mg/kg in humans (http://
home.fuse.net/clymer/minor/allometry.html), which is con-
sistent with the doses used in clinical settings. Bevacizumab
was given intraperitoneally at a concentration of 2.5 mg/kg/
dose (U87-MG) or 2.0 mg/kg/dose (U118-MG). Treatment
was continued until tumors grew to approximately 20 mm in
diameter at which point the mice were euthanized and
tumors quickly excised. 2-Deoxyglucose (Sigma, 500 mg/kg)
was delivered via intraperitoneal injection daily.
The details of cell culture, gene array analysis, histological
analysis and immunohistochemistry, DCA-treated spheroids,
and RNA isolation and quantitative RT-PCR (QPCR) analysis
are described in the Electronic supplementary material.
Statistical analysis
Statistical significance of observed differences among different
experimental groups was calculated using a two-tailed t test.
P values <0.05 were considered to be statistically significant.
Results
Establishment of the bevacizumab-resistance tumor model
U87-MG cell suspensions were subcutaneously injected into
the right flank of SCID mice. Treatment with bevacizumab
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(intraperitoneal injection of 10 mg/kg every 3 days) was
initiated when tumors averaged 100–200 mm3. Divergence
between the treated and non-treated cohorts was evident
1 week later, and at approximately day40, complete resis-
tance to bevacizumab was achieved (Fig. 1). Tumors were
excised separately for controls and treated cohorts at time
points when their average growth rates and sizes were
similar. An analogous response (i.e., initial response fol-
lowed by resistance) was observed using a submaximal dose
of bevacizumab (2.5 mg/kg; every 3 days by intraperitoneal
injection) in athymic nude mice. This will be described in
detail as part of the combination studies below. By
performing immunohistochemistry for standard vascular
markers (CD31 and CD34) followed by microvessel density
Fig. 1 Analysis of bevacizumab-treated U87-MG tumors. (A) Tumor
growth of U87-MG in vivo, treated with bevacizumab (BVC) or
vehicle control (CTRL), started from day12 to the end of the experi-
ment. mean±SE, N=5. Double asterisk (**) P<0.01. (B) Immunohis-
tochemical staining of tumor sections from CTRL or BVC-treated
tumors show increased hypoxia using HIF-1 and CA9, and a marker
of vessel morphology using CD34. Main images are ×10 magnification
and inset images ×20 magnification. Sections were stained and scored
for (C) vessel Q (CD31), (D) CA9 levels, and (E) necrosis. Mean±SE.
Single asterisk (*) P<0.05; triple asterisk (***) P<0.001
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counting, we confirmed that resistant tumors exhibit a sig-
nificantly sparser vasculature (Fig. 1). Therefore, therapeu-
tic resistance does not appear to be primarily related to
renewed vascularization due to a switch to alternative an-
giogenic growth factors, as shown in other models of bev-
acizumab resistance [7]. Expression of HIF-1α, as well as of
carbonic anhydrase IX (CA9), a robust HIF target and well-
established marker of hypoxia, was dramatically increased
in the resistant tumors, indicating that their growth contin-
ued in a significantly more oxygen-depleted environment
consistent with the data reported by Rapisarda et al. [8].
Molecular characterization of bevacizumab-resistance
model
In order to gain a comprehensive understanding of the
molecular processes that are associated with and potentially
critical for the resistance process, total RNA from treated
and non-treated tumors was subjected to expression analysis
using HGU133plus2 Affymetrix arrays. The full data set for
the Affymetrix array expression analysis is available at
http://www.ncbi.nlm.gog/geo/query/acc.cgi?acc=GSE37956.
A central theme in the bevacizumab-resistant tumors was
the coordinated activation of the HIF-driven transcription
program (Fig. 2). A large proportion of HIF targets
exhibited coordinated upregulation, in most cases with more
than one array probe. Notably, glycolytic HIF targets includ-
ing aldolases A and C, triosephosphate isomerase 1, and 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, as
well as the inducible glucose transporters GLUT1/SLC2A1
and GLUT3/SLC2A3, were robustly induced, pointing to an
increased reliance on glycolytic utilization of glucose. In
contrast, a significant repression in bevacizumab-resistant
tumors was seen at the level of pyruvate dehydrogenase
(PDH) alpha 1 and beta genes that govern the entry of
pyruvate into the tricarboxylic acid (TCA) cycle [9]. PDH
activity is inhibited by phosphorylation by pyruvate dehy-
drogenase kinases (PDK). PDK1 and PDK3 isoforms,
which are well-documented HIF targets [10–12], were
strongly upregulated in the bevacizumab-resistant tumors,
further supporting a biochemical shift away from oxidative
phosphorylation (OXPHOS) (Fig. 2). Arguably, the most
striking gene expression change in bevacizumab-resistant
tumors was the global downregulation of mitochondrial
metabolism genes, in particular, members of all five mito-
chondrial OXPHOS complexes (Fig. 2). Finally, several
components of the TCA cycle, including fumarate hydratase
(FH) and succinate dehydrogenase (SDH) were downregu-
lated (Fig. 2), which may contribute to tumor growth as they
also function as tumor suppressors [13].
KEGG pathway analysis confirmed that energy metabo-
lism represented one of the dominant changes associated
with the bevacizumab-resistant tumors. Thus, glycolytic
genes were most abundant among the upregulated genes,
together with genes belonging to fructose and mannose
metabolism, pentose phosphate pathway, amino sugar and
nucleotide sugar metabolism, and inositol phosphate metab-
olism (Supplementary Table S1A). The hypergeometric and
corrected hypergeometric p values were lower than 0.01 for
all these pathways. Conversely, among the downregulated
genes, OXPHOS was the top repressed pathway, with p
values lower than 1.00E-28, with pyruvate metabolism and
TCA cycle also exhibiting very highly significant repression
(Supplementary Table S1B). An additional signature ob-
served in the bevacizumab-resistant tumors was increased
endoplasmic reticulum stress and unfolded protein response.
In particular, the key mediators of these responses ATF4, 5,
6 and DDIT3/CHOP were all strongly overexpressed (Sup-
plementary Table S2), consistent with our previous obser-
vations that more severe hypoxia developing during the
course of antiangiogenic therapy activates non-HIF path-
ways [14].
In vitro effects of chronic hypoxia on mitochondrial
OXPHOS gene expression
To investigate whether hypoxia represents the primary cause
of the downregulation of mitochondrial respiration and Krebs
cycle genes, we undertook a comprehensive in vitro survey of
low oxygen effects in U87 cells. Interestingly, several
OXPHOS genes and Krebs cycle components that were found
downregulated in the arrays also responded by downregula-
tion in hypoxia, including ATP5A1, ATP5G3, NDUFA9, FH,
and MDH1 (Fig. 3). MRPL36 and MRPS11, two genes
thought to be critical in the assembly of the OXPHOS com-
plexes [15, 16], also showed downregulation in hypoxia,
similar to the effect of bevacizumab (Fig. 3). However, the
majority of the genes downregulated in the arrays failed to
exhibit downregulation during hypoxic exposure, suggesting
that other factors may be primarily responsible [17]. Reex-
amination of the arrays revealed that several transcription
factors that regulate mitochondrial gene expression (including
OXPHOS) were downregulated: NRF1, TFAM, and TFB2M
[18–20] (Supplementary Table S3).
Exploitation of the increased glycolytic gap: in vivo
synergism between bevacizumab and DCA
Based on the marked signature of increased HIF signal-
ing and decreased mitochondrial OXPHOS, we hypoth-
esized that the bevacizumab-resistant tumors would be
particularly sensitive to mitochondrial reactivators. The
top small molecule candidate from this class is DCA,
which inhibits PDK activity, thereby increasing the flux
of pyruvate into the mitochondria and promoting glu-
cose oxidation over glycolysis [21, 22]. Taking into
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account the well-recognized side effects of antiangio-
genic therapy as well as of DCA, for the assessment
of the drug combination, we chose a submaximal dose
of the antiangiogenic agent (2.5 mg/kg; every 3 days by
Fig. 2 Gene expression changes in control versus bevacizumab-
treated groups. X-axis represents control and bevacizumab-treated
tumors. Array data were preprocessed using GCRMA, normalized
using quantile normalization and log base 2. Expression is shown
standardized per gene (Z values; color key at the top). Y-axis: gene
symbols shown on the right. Blue bands on side indicate mitochondrial
gene complexes (from light blue=I to dark blue=V). Green band
indicates Krebs cycle genes. Red band indicates HIF targets
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intraperitoneal injection), a strategy which is widely
employed in vivo [23]. This approach is also anticipated
to increase our ability to detect synergism between the
two drugs, both from the standpoint of tumor response
and effects on HIF signaling. Indeed, treatment with
bevacizumab and DCA dramatically blocked tumor
growth compared to each drug alone (Fig. 4A and
Supplementary Fig. S1). In order to assess the general-
ity of the response, we investigated an additional GBM
cell type, U118. The response in U118-based grafts was
also much more robust with the combination, compared
to the individual drugs (Fig. 4B and Supplementary Fig.
S1).
The efficacy of glycolytic inhibitors in overcoming resis-
tance to bevacizumab has been previously proposed [24]
without experimental confirmation. DCA and 2-DG were
discussed together as part of this concept. However, when 2-
DG was tested in parallel to DCA, no additive effect to
Fig. 3 Downregulation of metabolic mitochondrial genes in
bevacizumab-resistant tumors. Quantitative PCR analysis was per-
formed to investigate the effects of BVC treatment or hypoxia on
U87 cells. For normoxia versus hypoxia comparisons, cells were
incubated at 1 % oxygen for 72 h. The following mitochondrial genes
were tested: (A) mitochondrial ribosomal genes, (B) Krebs cycle
enzymes, and (C) electron transport complex I and V components.
Gene levels are expressed as fold changes by comparison in vivo to
PBS controls and in vitro to normoxic controls. Mean±SE. Single
asterisk (*) P<0.05; double asterisk (**) P<0.01; triple asterisk
(***) P<0.001
Fig. 4 DCA amplifies the effects of BVC on tumor growth in vivo. (A)
Tumor growth of U87-MG in vivo, treated with either CTRL, BVC,
DCA, or BVC/DCA, starting from day7 until the end of the experi-
ment. Mean±SE, N=4–6. Single asterisk (*) P<0.05; (B) tumor
growth of U118 in vivo, treated with either CTRL, BVC, DCA, or
BVC/DCA. The U118 tumors were slow growing, and so, day0 is
treatment start time. Mean±SE, N=4–8. Single asterisk (*) P<0.05;
double asterisk (**) P<0.01; (black stars is comparison to CTRL, gray
stars to BVC alone); (C) growth of U87-MG spheroids treated with
either vehicle control (CTRL) or 10 mM DCA. Spheroids were
allowed to grow to 0.2 mm3 before being treated with DCA every
3 days. NB: error bars are small and within the symbols. (D) Pictures
(at ×5 magnification) show representative images of the CTRL and
DCA-treated spheroids
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bevacizumab was noticed. This was despite the transient
effect of 2-DG as a single agent, administered at the con-
centration described in the literature (Supplementary Fig.
S2). Thus, mitochondrial reactivation and direct inhibition
of glycolysis have different effects in combination with
bevacizumab.
In vitro effects of DCA
Spheroid models provide a system of intermediate com-
plexity between standard two-dimensional culture sys-
tems and tumors in vivo because of oxygen and nutrient
gradients. Unlike monolayer systems, expanding sphe-
roids mimic the increased avascularity of the in vivo
structures growing in presence of bevacizumab. U87
spheroids were generated, as described [25], and grown
for 7 days until they reached 0.2 mm3. Spheroids of this
size are large enough to allow diffusion of a drug
across the spheroid but also are starting to form a small
central area of hypoxia and display gradients of
nutrients, pH and O2. Robust divergence of the growth
kinetics between DCA-treated and non-treated groups
was noticed after 3 days of treatment. This effect was
persistent, and from 6 days onward, DCA significantly
compromised spheroid expansion (Fig. 4C, D).
Effect of bevacizumab and DCA combination on HIF
targets and histological markers of tumor growth
In order to address whether the effect of the combina-
tion on tumor growth was primarily determined by
increased cell death or decreased proliferation, we per-
formed histological analyses on these tumors, using
well-established markers. Necrosis was higher in the
treated tumors compared to the untreated ones, but no
significant difference was observed between the drugs
alone or in combination (Fig. 5). Proliferation rate, as
evaluated by quantification of Ki-67 (MIB-1) staining,
was significantly lower in the combination group com-
pared to both untreated and bevacizumab-only tumors,
suggesting that the effect of the combination was pre-
dominantly cytostatic (Fig. 5). We, then, assessed the
effects of the drug combination on HIF signaling, using
a combination of immunohistochemistry/quantitative RT-
PCR (Figs. 5, 6). Surprisingly, while known to increase
oxygen consumption in various experimental systems,
DCA alone was not sufficient to measurably increase
the expression of the HIF targets in vivo. However, in
combination with bevacizumab, CA9 expression in-
creased dramatically in the viable U87 tumor cells. In
U118, on the other hand, submaximal bevacizumab
alone led to a dramatic increase in all HIF targets
tested, without further measurable increase in the
combination-treated tumors (Fig. 6 and Supplementary
Fig. S3). However, the major caveat is that the tumors
surviving in the presence of the combination were dra-
matically smaller and practically stationary, factors that
should mitigate the extent of hypoxia.
Discussion
The main goal of our study was to gain a deeper under-
standing of tumor adaption to bevacizumab, by identifying
pathways that are associated with resistance, with a partic-
ular focus on metabolic responses. We concentrated on a
heterotopic rather than an orthotopic model, primarily to
ensure the feasibility of monitoring neoplastic growth and
escape. Additionally, as subcutaneous tumors reach signifi-
cantly larger volumes than their orthotopic counterparts,
they are arguably more relevant for modeling advanced
and hypoxic malignancies.
In a recently published orthotopic model of GBM,
increased hypoxia post-bevacizumab has been reported
[24, 26]; however, investigating long-term growth differ-
ences is less feasible in such systems. Despite the
“classic” status of tumor metabolism in cancer research
and its recent revival, no drug that acts primarily at this
level has been approved for routine clinical use [27].
DCA, a small molecule which crosses the blood brain
barrier [22], showed promising results in a clinical trial
in GBM in combination with surgery, temozolomide,
and radiation [21], with multiple additional trials cur-
rently underway http://clinicaltrials.gov/ct2/results?term=
+Dichloroacetate). However, the effect of DCA as a
single agent is transient at best, and our tumor models
certainly reflect this limitation. A recent study discussed
the possibility that bevacizumab treatment should sensi-
tize tumors to both 2-DG and DCA [24], but these
predictions have been confirmed only for DCA in our
hands. The lack of a measurable additive or synergistic
effect of 2-DG was unlikely due to biological inactivity
or inadequate dosing as it was transiently effective as a
single agent. Questions remain as to the mechanism of
DCA-mediated tumor inhibition in the presence of bev-
acizumab. While DCA was reported to block angiogen-
esis by itself [21], measurement of mean vessel density
did not confirm this in our system.
DCA has been shown to exhibit increased cytotoxic effects
under hypoxia in a variety of cell lines [28]. The current
paradigm is that DCA accelerates oxygen consumption by
mitochondrial reactivation and further decreases local oxygen
tension [29], thus posing an additional challenge on tumor
cells to survive and/or proliferate. Moreover, it has been
demonstrated that in cells "hardwired" to selectively utilize
glycolysis for ATP generation due to mitochondrial DNA
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mutations, forced OXPHOS induced by DCA had a toxic
effect. DCA also exhibits synergistic cytotoxicity in
vitro in combination with cisplatin and topotecan, two
antineoplastic agents known to damage mitochondrial
DNA [30]. One could speculate that the downregulation of
mitochondrial genes in the bevacizumab-resistant tumors rep-
resents a form of mitochondrial dysfunction that sensitizes to
the effects of DCA.
Interestingly, the effect of DCA, as a single agent, on
HIF targets in xenografts was subtle at best despite its
Fig. 5 Effect of bevacizumab
and DCA on U87-MG tumor
histology. (A) Immunohisto-
chemical staining for CA9,
CD31, Ki-67 (MIB-1), and ne-
crosis in FFPE sections of U87-
MG tumor xenografts treated
with BVC, DCA, a combination
of BVC and DCA, or vehicle
control (CTRL). Quantification
of (B) percentage of the viable
tissue positive for CA9; (C)
vessel score, VQ, (CD31); (D)
proliferation index, PQ, (Ki-
67); and (E) necrosis. All
images are shown at ×20 mag-
nification. Mean±SE. Single
asterisk (*) P<0.05; double as-
terisk (**) P<0.01; triple as-
terisk (***) P<0.001
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well-recognized positive effect on oxygen consumption.
In contrast, together with bevacizumab, DCA led to
increased expression of most HIF targets tested in the
surviving tumors versus bevacizumab alone. A possible
explanation for these results is that forced OXPHOS
induced by DCA in the presence of very low levels of
oxygen may lead to increased reactive oxygen species
production, which, in turn, may contribute to additional
induction of HIF [31]. Additionally, or alternatively,
DCA in the presence of bevacizumab may lead to a
further decrease in the local oxygen concentration to
levels where the induction of HIF targets becomes more
evident by quantitative RT-PCR assay. In addition to
increased CA9 expression, enhanced expression of the
HIF targets PDK1, 3 and GLUT1 was observed in the
tumors surviving in the presence of the drug combina-
tion in either U87 or U118 cells. This may reflect a
more dramatic “last resort” metabolic shift critical for
tumor cell survival. In particular, increased expression
of PDK1/3 may be part of a “final attempt” by the
tumor cells to counteract in part the effect of DCA
and inactivate mitochondrial OXPHOS. Such metabolic
shifts in tumors surviving in the presence of bevacizu-
mab plus DCA may also provide important clues on
how to further increase the efficacy of this combination.
For example, one could speculate that the resistant
tumors may exhibit at least some sensitivity to a further
escalation of DCA concentration although toxicity of
this compound may become a limiting factor. Upregu-
lation of tumor-specific CA9 may also play an impor-
tant role in the survival of the combination-treated
tumors as it accelerates the elimination of excess CO2
generated from the reactivation of the Krebs cycle [25].
Therefore, CA9 inhibitors which have recently shown
promising anticancer effects [32, 33] may be regarded
as realistic candidates for a third component of a com-
bination strategy.
In conclusion, molecular dissection of tumor adaptation
to anti-VEGF agents may offer valuable clues for building
more efficient combinations that include targeting cancer
metabolism.
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